Teva Pharmaceutical Industries (NYSE:TEVA) has been assigned a $16.00 target price by equities research analysts at BTIG Research in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 6.17% from the stock’s previous close.

A number of other research firms also recently weighed in on TEVA. Cantor Fitzgerald set a $10.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Monday. Zacks Investment Research raised Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Goldman Sachs Group reaffirmed a “neutral” rating and set a $21.00 price target (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 31st. Morgan Stanley set a $15.00 price target on Teva Pharmaceutical Industries and gave the stock an “underweight” rating in a research report on Thursday, October 5th. Finally, Piper Jaffray Companies reaffirmed a “neutral” rating and set a $23.00 price target (down previously from $28.00) on shares of Teva Pharmaceutical Industries in a research report on Friday, August 4th. Seven investment analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $21.72.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) opened at $15.07 on Tuesday. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $38.49. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The stock has a market capitalization of $14,925.04, a P/E ratio of 3.39 and a beta of 0.52.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Capital Research Global Investors boosted its holdings in shares of Teva Pharmaceutical Industries by 13.8% in the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after buying an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Teva Pharmaceutical Industries by 11.1% during the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares during the last quarter. FMR LLC lifted its holdings in Teva Pharmaceutical Industries by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Macquarie Group Ltd. lifted its holdings in Teva Pharmaceutical Industries by 350.3% during the 3rd quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after purchasing an additional 3,429,448 shares during the last quarter. Finally, Capital World Investors lifted its holdings in Teva Pharmaceutical Industries by 41.9% during the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after purchasing an additional 3,268,200 shares during the last quarter. 52.05% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries (TEVA) PT Set at $16.00 by BTIG Research” was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/30/teva-pharmaceutical-industries-teva-pt-set-at-16-00-by-btig-research.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.